Compare Stocks: LPTX, STRO, IFRX, and EBS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.21 -0.3%	$6.69	$4.36 ▼ $14.06	$319.43M	2.34	1.48 million shs	998,572 shs
IFRX InflaRx	$2.22 -0.4%	$2.02	$0.80 ▼ $2.95	$327.16M	2.52	1.04 million shs	393,942 shs
LPTX Leap Therapeutics		$2.05	$0.00 ▼ $0.00	$84.95M	-0.06	40.67 million shs	760.56 million shs
STRO Sutro Biopharma	$20.07 -2.3%	$24.59	$7.15 ▼ $43.85	$340.57M	1.48	281,286 shs	124,764 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-0.32%	+4.90%	-17.80%	-23.17%	-20.84%
IFRX InflaRx	-0.45%	-0.45%	+25.42%	+20.65%	+28.32%
LPTX Leap Therapeutics	0.00%	0.00%	0.00%	0.00%	+204,999,900.00%
STRO Sutro Biopharma	-2.29%	-1.86%	-20.04%	-23.07%	+98.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.21 -0.3%	$6.69	$4.36 ▼ $14.06	$319.43M	2.34	1.48 million shs	998,572 shs
IFRX InflaRx	$2.22 -0.4%	$2.02	$0.80 ▼ $2.95	$327.16M	2.52	1.04 million shs	393,942 shs
LPTX Leap Therapeutics		$2.05	$0.00 ▼ $0.00	$84.95M	-0.06	40.67 million shs	760.56 million shs
STRO Sutro Biopharma	$20.07 -2.3%	$24.59	$7.15 ▼ $43.85	$340.57M	1.48	281,286 shs	124,764 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-0.32%	+4.90%	-17.80%	-23.17%	-20.84%
IFRX InflaRx	-0.45%	-0.45%	+25.42%	+20.65%	+28.32%
LPTX Leap Therapeutics	0.00%	0.00%	0.00%	0.00%	+204,999,900.00%
STRO Sutro Biopharma	-2.29%	-1.86%	-20.04%	-23.07%	+98.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.17	Hold	$10.00	61.03% Upside
IFRX InflaRx	2.63	Moderate Buy	$7.33	230.33% Upside
LPTX Leap Therapeutics	1.00	Sell	N/A	N/A
STRO Sutro Biopharma	3.00	Buy	$47.30	135.68% Upside

Current Analyst Ratings Breakdown

Latest LPTX, STRO, IFRX, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/21/2026	EBS Emergent Biosolutions	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight
8/13/2026	STRO Sutro Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$41.00 ➝ $34.00
8/13/2026	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$60.00
8/11/2026	EBS Emergent Biosolutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
8/7/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/7/2026	STRO Sutro Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$48.00
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.90M	0.43	$3.65 per share	1.70	$6.66 per share	0.93
IFRX InflaRx	-$10.10K	-32,388.57	N/A	N/A	$1.15 per share	1.93
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A
STRO Sutro Biopharma	$45.70M	7.28	N/A	N/A	($6.23) per share	-3.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	8.39	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.22	N/A	N/A	N/A	N/A	-247.44%	-146.51%	N/A
STRO Sutro Biopharma	-$191.09M	-$11.97	N/A	N/A	N/A	-395.25%	N/A	-88.12%	11/5/2026 (Estimated)

Latest LPTX, STRO, IFRX, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	STRO Sutro Biopharma	-$2.19	-$2.33	-$0.14	-$2.33	$11.96 million	$9.84 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.70	5.42	2.95
IFRX InflaRx	N/A	8.22	8.22
LPTX Leap Therapeutics	N/A	1.34	1.34
STRO Sutro Biopharma	N/A	3.32	3.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
IFRX InflaRx	42.39%
LPTX Leap Therapeutics	30.46%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
IFRX InflaRx	16.30%
LPTX Leap Therapeutics	4.30%
STRO Sutro Biopharma	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	51.27 million	48.20 million	Optionable
IFRX InflaRx	60	147.37 million	123.35 million	Optionable
LPTX Leap Therapeutics	40	41.44 million	39.66 million	N/A
STRO Sutro Biopharma	240	16.58 million	16.28 million	Optionable

LPTX, STRO, IFRX, and EBS Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Makes New Investment in Sutro Biopharma, Inc. $STRO

September 5 at 5:44 AM | marketbeat.com

Merck & Co. Inc. Invests $9.04 Billion in Sutro Biopharma, Inc. $STRO

August 18, 2026 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by Analysts

August 15, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

August 14, 2026 | theglobeandmail.com

Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright

August 14, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $34.00 at Citizens Jmp

August 13, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush

August 13, 2026 | marketbeat.com

STRO stock plummets 15% — what drove the selloff?

August 12, 2026 | msn.com

Why is Sutro Biopharma Stock Falling On Wednesday?

August 12, 2026 | benzinga.com

Sutro Biopharma (NASDAQ:STRO) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

August 12, 2026 | marketbeat.com

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

August 12, 2026 | globenewswire.com

News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts

May 28, 2026 | finance.yahoo.com

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results

May 17, 2026 | finance.yahoo.com

Wedbush upgrades Sutro Biopharma (STRO)

May 16, 2026 | msn.com

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

May 14, 2026 | globenewswire.com

Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program

May 1, 2026 | insidermonkey.com

Mizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendation

May 1, 2026 | msn.com

Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell

May 1, 2026 | seekingalpha.com

Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now

April 29, 2026 | finance.yahoo.com

Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - Slideshow

April 24, 2026 | seekingalpha.com

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

April 19, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LPTX, STRO, IFRX, and EBS Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.21 -0.02 (-0.32%)

As of 09/4/2026 03:58 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

InflaRx NASDAQ:IFRX

$2.22 -0.01 (-0.45%)

As of 09/4/2026 04:00 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Leap Therapeutics NASDAQ:LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Sutro Biopharma NASDAQ:STRO

$20.07 -0.47 (-2.29%)

As of 09/4/2026 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPTX, STRO, IFRX, and EBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPTX, STRO, IFRX, and EBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPTX, STRO, IFRX, and EBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LPTX, STRO, IFRX, and EBS Company Descriptions

Emergent Biosolutions NYSE:EBS

InflaRx NASDAQ:IFRX

Leap Therapeutics NASDAQ:LPTX

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LPTX, STRO, IFRX, and EBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LPTX, STRO, IFRX, and EBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LPTX, STRO, IFRX, and EBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LPTX, STRO, IFRX, and EBS Company Descriptions

Emergent Biosolutions NYSE:EBS

InflaRx NASDAQ:IFRX

Leap Therapeutics NASDAQ:LPTX

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools